OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 9th 2020

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Dr. Ruan on Stratifying Risk in MCL

June 9th 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Dr. Neelapu on ALLO-501 Plus ALLO-647 in Relapsed/Refractory B-Cell Lymphomas

June 8th 2020

Sattva Neelapu, MD, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Dr. Ruan on Stratifying Risk in MCL

June 8th 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 8th 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian Cancer

June 8th 2020

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Dr. Lee on the Mechanism of Action of Cirmtuzumab in MCL or CLL

June 8th 2020

Hun Ju Lee, MD, an associate professor of medicine in the Department of Lymphoma & Myeloma and the Jessica and Jeffrey Brue Endowed Professor of Lymphoma Research at The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Lilenbaum on Future Directions With Immunotherapy in Lung Cancer

June 7th 2020

Rogerio C. Lilenbaum, MD, discusses the promising future direction of immunotherapy in patients with advanced lung cancer.

Dr. Swisher on the Phase III VELIA Results in Ovarian Cancer

June 7th 2020

Elizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

Dr. Abdul-Hay on the Use of HCT-CI to Guide Transplant Eligibility in ALL

June 6th 2020

Mohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).

Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

June 6th 2020

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Dr. Mateos on the Ongoing CANOVA Trial in t(11;14) Multiple Myeloma

June 6th 2020

María-Victoria Mateos, MD, PhD, discusses the design of the ongoing phase 3 CANOVA trial in patients with relapsed/refractory t(11;14) multiple myeloma.

Dr. Bose on the Utility of Ruxolitinib in Myelofibrosis

June 6th 2020

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Dr. Morris on Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer

June 5th 2020

Michael J. Morris, MD, discusses the impact of prostate-specific membrane antigen-targeted imaging with 18F-DCFPyL-PET/CT on the clinical management of patients with prostate cancer.

Dr. Lopategui on the Evolution of Targeted Therapies in NSCLC

June 5th 2020

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced Cancer

June 5th 2020

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Dr. Husain on Common Misconceptions in Lung Cancer

June 5th 2020

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Dr. Hoffman on the Current Polycythemia Vera Treatment Paradigm

June 5th 2020

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

June 5th 2020

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.